Device Tl

Catalyft Pl Expandable Interbody System

Payments companies reported to CMS as associated with Catalyft Pl Expandable Interbody System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$5.3Massociated payments (2023-2025)
1,608clinicians with associated payments
1company reporting

By year

2023 $160K
2024 $165K
2025 $5.0M

Payments reported as associated with Catalyft Pl Expandable Interbody System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurological Surgery $4.7M
Orthopaedic Surgery of The Spine $447K
Orthopaedic Surgery $126K
Physician Assistant $9,104
Surgical $8,178
Family $2,987

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Catalyft Pl Expandable Interbody System

These are the largest totals companies reported as associated with Catalyft Pl Expandable Interbody System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Kevin Foley Memphis, TN Neurological Surgery $3,929,838.00
Charles Branch Advance, NC Neurological Surgery $527,841.38
Mladen Djurasovic Louisville, KY Orthopaedic Surgery of The Spine $329,733.10
David Polly Minneapolis, MN Orthopaedic Surgery $26,675.00
Christopher Holland Concord, NC Neurological Surgery $26,673.86
Lali Sekhon Reno, NV Neurological Surgery $15,851.05
Paul Gause Scottsdale, AZ Orthopaedic Surgery $11,281.02
Robert Hart Seattle, WA Orthopaedic Surgery $11,272.37
Joseph Osorio San Diego, CA Neurological Surgery $10,802.30
David Xu Columbus, OH Neurological Surgery $10,685.83

Prescribed Catalyft Pl Expandable Interbody System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.